FRANKFURT, Feb 3 (Reuters) - Britain’s GlaxoSmithKline and German biotech firm CureVac struck a deal to develop next-generation vaccines against COVID-19 that target several variants in one product.
In a joint statement on Wednesday, the partners said they were targeting a possible launch in 2022.